Company Filing History:
1 out of 16 
1 out of 6 Years Active: 2010-2013
Title: **Peter Harris Silverstone: An Innovator in Therapeutic Applications**
Introduction
Peter Harris Silverstone is a notable inventor based in Alberta, Canada, recognized for his contributions to pharmaceutical innovation. With a robust portfolio of two patents, Silverstone has demonstrated a commitment to advancing therapeutic methodologies, particularly in the realm of bupropion and its applications.
Latest Patents
Silverstone's latest patents focus on the therapeutic applications of bupropion hydrobromide. The first patent details a method aimed at reducing the incidences of bupropion-induced seizures through the coadministration of a bromide salt alongside a bupropion salt. The second patent describes formulations of bupropion hydrobromide, outlining their use in treating various conditions. These innovations reflect Silverstone's dedication to enhancing patient safety and treatment efficacy.
Career Highlights
Throughout his career, Peter Harris Silverstone has worked with prominent organizations in the pharmaceutical industry. His experiences at Biovail Laboratories International S.r.l. and Valeant International Bermuda have been instrumental in shaping his expertise and enhancing his ability to innovate within the field. These roles have provided him with the platform to develop and commercialize his inventions effectively.
Collaborations
In his professional journey, Silverstone has collaborated with esteemed colleagues, including fellow innovator Robert Parry Williams. Such partnerships not only foster creativity but also enhance the practical application of their collective research and inventions.
Conclusion
Peter Harris Silverstone stands out as a distinguished inventor in Alberta, Canada, contributing significantly to the field of therapeutic applications for bupropion. His innovative patents and collaborations with industry professionals underscore his impact on healthcare, paving the way for safer and more effective treatment options. Silverstone's work exemplifies the essence of innovation in the pharmaceutical domain.